These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34098559)

  • 21. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
    Suzuki D; Ichie T; Hayashi H; Sugiura Y; Sugiyama T
    Pharmazie; 2017 Feb; 72(2):118-122. PubMed ID: 29441865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.
    Lee CT; Wu IW; Chiang SS; Peng YS; Shu KH; Wu MJ; Wu MS
    J Nephrol; 2015 Feb; 28(1):105-13. PubMed ID: 24840781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
    Chey WD; Lembo AJ; Rosenbaum DP
    Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications.
    Yee J; Rosenbaum D; Jacobs JW; Sprague SM
    Am J Nephrol; 2021; 52(7):522-530. PubMed ID: 34515051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
    Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease.
    Lin T; Al-Makki A; Shepler B
    J Pharm Pharm Sci; 2022; 25():77-83. PubMed ID: 35041802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
    Floege J; Covic AC; Ketteler M; Rastogi A; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Kidney Int; 2014 Sep; 86(3):638-47. PubMed ID: 24646861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial.
    Akizawa T; Origasa H; Kameoka C; Tsukada J; Kuroishi K; Yamaguchi Y
    Ther Apher Dial; 2016 Dec; 20(6):588-597. PubMed ID: 27896908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease.
    Fathallah-Shaykh S; Drozdz D; Flynn J; Jenkins R; Wesseling-Perry K; Swartz SJ; Wong C; Accomando B; Cox GF; Warady BA
    Pediatr Nephrol; 2018 Feb; 33(2):325-333. PubMed ID: 28900759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update on tenapanor to treat hyperphosphatemia.
    Cianciolo G; Barbuto S; Iacovella F; La Manna G; Galassi A; Ciceri P; Cozzolino M
    Drugs Today (Barc); 2022 Jan; 58(1):33-53. PubMed ID: 35107092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.
    Fouque D; Vervloet M; Ketteler M
    Drugs; 2018 Aug; 78(12):1171-1186. PubMed ID: 30022383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.
    King AJ; Kohler J; Fung C; Jiang Z; Quach A; Kumaraswamy P; Chertow GM; Rosenbaum DP
    Am J Physiol Renal Physiol; 2021 Jan; 320(1):F133-F144. PubMed ID: 33283643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
    Johansson S; Rosenbaum DP; Knutsson M; Leonsson-Zachrisson M
    Clin Exp Nephrol; 2017 Jun; 21(3):407-416. PubMed ID: 27368672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
    Kendrick J; Parameswaran V; Ficociello LH; Ofsthun NJ; Davis S; Mullon C; Kossmann RJ; Kalantar-Zadeh K
    J Ren Nutr; 2019 Sep; 29(5):428-437. PubMed ID: 30679076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenapanor in Chinese ESRD patients with hyperphosphatemia on haemodialysis: a randomised, phase 3 trial.
    Gan L; Xing L; Xu Y; Zhou L; Jiang H; Sun X; Guan T; Luo P; Wang J; Sun F; Guo Z; Guo M; Gao J; Wei G; Zhong W; Zhou Y; Zuo L
    Clin Kidney J; 2024 Jan; 17(1):sfad216. PubMed ID: 38186905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.